| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
The Supreme Court on Tuesday seemed unlikely to limit access to mifepristone, a key medication used in more than 60 percent of U.S. abortions and first approved more than two decades ago.
A majority of justices from across the ideological spectrum expressed skepticism that the antiabortion doctors challenging the government's loosening of regulations have sufficient legal grounds — or standing — to bring the lawsuit.
During oral argument, the government and the drug company that makes the medication emphasized the safety of the drug but also focused much of their arguments on standing.
Erin Hawley, lawyer for Alliance for Hippocratic Medicine, argued that mifepristone is dangerous, even though multiple studies have shown it to be overwhelmingly safe. She says that if complications emerge from medication abortions, antiabortion doctors are forced to choose between helping a woman with a life-threatening condition and violating their conscience.
The justices are examining rule changes in 2016 and 2021 that, among other things, made the drug available by mail and from a medical provider other than a doctor.
